LONDON, February 24, 2010 /PRNewswire/ -- First Quarter of 2010 has shown some early signs of resurgence in life science IPO's that are already underway or planned. BioTrinity, the UK's Premier Biopartnering and Investment Conference, will be focusing on the evidence for early success and the prospects for the remainder of the year and into 2011 in a series of panel discussions aimed at understanding the current marketplace, the way companies can maximise their chances of a successful float and the support the City can give to ensure success.
This is the 4th Annual BioTrinity Conference, which has evolved into the UK's largest and arguably most successful Biopartnering and Investment Conference. Because of its success the conference has outgrown the Kassam Stadium, its home for the past two years and will now take place at the Newbury Racecourse April 12-14th. A key driver for the success of the conference has been its focused programme of discussions and panel sessions tackling the current themes of most interest to the biotechnology industry and more widely for the life sciences industries in general.
The green shoots of recovery in the life sciences IPO market is a key consideration for early venture investors as they look for significant financial inflection points that will generate shareholder value and equip their companies to take their products and technologies through to commercialisation. A healthy IPO market is a key element of this and therefore a focus of the BioTrinity programme for this year.
Investment Banker James Steel, Director of Corporate Finance at KBC Peel Hunt will lead the discussion helping life sciences companies to understand the implications of the recent rise in IPO activity on both sides of the Atlantic. His colleague Senior Healthcare Analyst, Paul Cuddon, will provide additional input and insights into the City's perception of life science companies following the downturn and also give views on those areas of life sciences which are more likely to be IPO candidates on the UK markets over the coming months. .
These perspectives will be complimented by Ian Paling, CEO and Exec Chairman of privately-held CellCoTec. As CEO of Corin Group Plc Ian also guided that company through an IPO in 2002 and subsequently grew it into a highly regarded publicly quoted orthopaedic company. BioTrinity is also able to announce that Vernalis' CEO; Ian Garland will join this panel discussion in the same week that Vernalis plc announced plans to raise GBP30m on the public markets, These perspectives will be provided by a leading venture capital house.
As part of it role in fostering partnership building, BioTrinity features an exclusive pre-conference invitation-only five course wine and tasting dinner at the Vineyard at Stockcross which is uniquely designed to provide a convivial forum to encourage investors in the sector to develop syndicates, exchange knowledge and cooperate on future deals.
For further information, please contact: Jon Rees CEO, OBN Tel: +44(0)1865-594642 Anna Dunphy De Facto Communications Tel: +44(0)20-7861-3838
SOURCE: Oxfordshire Bioscience Network (OBN)
CONTACT: For further information, please contact: Jon Rees, CEO, OBN, Tel:+44(0)1865-594642; Anna Dunphy, De Facto Communications, Tel:+44(0)20-7861-3838.
Comments